Get to know our clinical trials
A 72-week, placebo-controlled, parallel-group clinical trial to evaluate the efficacy and safety of VHB937 in participants with early-stage Alzheimer's disease, followed by an extension phase.
THE GOAL OF THIS TRIAL IS TO DETERMINE WHETHER TREATMENT WITH VHB937 IS SAFE AND BENEFICIAL FOR PEOPLE WITH EARLY SYMPTOMS OF AD. THE TRIAL WILL EVALUATE THE SAFETY OF VHB937, AS WELL AS ITS EFFECTS ON MEMORY AND OTHER THINKING SKILLS, DAILY ACTIVITIES, AND CHANGES IN THE BRAIN. IT WILL ALSO OBSERVE AND MEASURE HOW THE BODY PROCESSES VHB937 AND HOW THE BODY RESPONDS TO IT.
Technical Summary
- A 72-WEEK, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VHB937 IN PARTICIPANTS WITH EARLY-STAGE ALZHEIMER'S DISEASE, FOLLOWED BY AN EXTENSION PHASE.
- Code EudraCT: 2024-516966-12
- Protocol number: CVHB937A12201
- Promoter: Novartis
- Molecule/Drug: VHB937
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.